Evidence map›Paper›PMID 36972230›Full record

ArticlePloS one2023

IL-12p40 is essential but not sufficient for Francisella tularensis LVS clearance in chronically infected mice.

Lara R Mittereder, Jonathan Swoboda, Roberto De Pascalis, Karen L Elkins

Open access · goldFull text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. The immune response toFrontiers in microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lara R MitterederCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.ORCID 0000-0003-3558-0140
Jonathan SwobodaCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Roberto De PascalisCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Karen L ElkinsCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Center for Biologics Evaluation and Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IL-12p40 plays an important role in F. tularensis Live Vaccine Strain (LVS) clearance that is independent of its functions as a part of the heterodimeric cytokines IL-12p70 or IL-23. In contrast to WT, p35, or p19 knockout (KO) mice, p40 KO mice infected with LVS develop a chronic infection that does not resolve. Here, we further evaluated the role of IL-12p40 in F. tularensis clearance. Despite reduced IFN-γ production, primed splenocytes from p40 KO and p35 KO mice appeared functionally similar to those from WT mice during in vitro co-culture assays of intramacrophage bacterial growth control. Gene expression analysis revealed a subset of genes that were upregulated in re-stimulated WT and p35 KO splenocytes, but not p40 KO splenocytes, and thus are candidates for involvement in F. tularensis clearance. To directly evaluate a potential mechanism for p40 in F. tularensis clearance, we reconstituted protein levels in LVS-infected p40 KO mice using either intermittent injections of p40 homodimer (p80) or treatment with a p40-producing lentivirus construct. Although both delivery strategies yielded readily detectable levels of p40 in sera and spleens, neither treatment had a measurable impact on LVS clearance by p40 KO mice. Taken together, these studies demonstrate that clearance of F. tularensis infection depends on p40, but p40 monomers and/or dimers alone are not sufficient.

Indexed as

Interleukin-12 Subunit p40TularemiaAnimalsBacterial VaccinesCytokinesFrancisella tularensisInterleukin-12MiceMice, Inbred C57BLMice, KnockoutBacterial VaccinesCytokinesInterleukin-12Interleukin-12 Subunit p40

Identifiers

PMID36972230
PMCPMC10042368
OpenAlexW4361017577

What OpenQuestion holds

Textfull text, public
LicenceCC0
measurements read24
identifiers read4
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.